BioLife Solutions officer plans $48.6K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions, Inc. (BLFS) officer Karen Foster reported a planned sale of 2,577 common shares, with an aggregate market value of $48,576.45 and an approximate sale date of March 23, 2026. She acquired 2,577 shares from the issuer through exercise of stock options on March 23, 2026, paying cash. The reported date for plan adoption or instruction, if relying on Rule 10b5-1, is December 4, 2025. Prior sales are identified as Rule 10b5-1 transactions.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior Rule 10b5-1 sales did Karen Foster report for BLFS?
AI-generated analysis. How Rhea-AI works. Not financial advice.